A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study With an Initial Treatment Period Followed by a Randomized-Withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Bimekizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms BE READY
- Sponsors UCB Biopharma
- 14 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Feb 2018 Planned End Date changed from 29 Feb 2020 to 1 Feb 2020.
- 15 Feb 2018 Planned initiation date changed from 1 Jan 2018 to 1 Feb 2019.